Enhanced Medical Nutrition

EMN's flagship product is ENROUTE®, a complete surgical nutrition program. This four-week regimen, used two weeks before and two after surgery, consists of two patented, multi-nutrient drink formulas intended to manage the unique metabolic and physiological demands of a surgical event. The 'BUILD' formula contains protein, creatine, calcium, and vitamin D to maintain muscle mass and support bone health, while the 'PREPARE' formula is a complex carbohydrate blend to ready the body for the procedure. The program aims to reduce complication risks, promote wound healing, enhance immune function, and accelerate overall recovery. ENROUTE® is available in various flavors and dairy or plant-based options, and can only be acquired through a surgeon's recommendation. Another key product is ISOlution®, a clinical-grade, unflavored whey protein isolate powder designed to help patients with high protein requirements. It can be mixed into foods and drinks or administered via a feeding tube and contains a high concentration of leucine, an amino acid vital for stimulating muscle growth.

The company has achieved several financial milestones, signaling investor confidence in its approach. In February 2019, EMN secured a $1.2 million seed round to support commercial operations in North America and Southeast Asia. This was followed by a pre-Series A financing round in October 2023 with investors including dsm-firmenich Venturing and The Kale Fund. In January 2025, the company announced an oversubscribed $5 million Series A round, co-led by dsm-firmenich Venturing and the corporate venture arm of Ajinomoto Co., Inc., with participation from PeakBridge and others. These funds are earmarked for scaling the North American expansion of the ENROUTE® program.